SIPEx: SAXA
INTELLECTUAL
PROPERTY EXCHANGE
A New Paradigm for In-Licensing & Out-Licensing Life Science Patents


What We Do
SIPEx is poised to play a significant role in the evolution of the traditional market for IP assets, not only by making the transactional process much easier, but also by facilitating relationships between licensors and licensees via a comprehensive and secure online marketplace.
Who We Are
SAXA was founded by two entrepreneurial lawyers with over 50 years of combined experience in Big Pharma, finance, law, international tax, and government. Both are graduates of Georgetown University Law Center in Washington, DC. The company takes its name from the university’s Latin motto: “Hoya Saxa.”


Competitors?
There are at least a dozen websites today that appear to be online IP marketplaces. However, that appearance is misleading. Some of these sites are managed by brokers, who merely facilitate negotiations between licensors and licensees regarding assets previously identified by the parties. Other sites are simply bulletin boards, briefly listing IP for out-license and in-license, with additional information only available offline by contacting the listing entity. SIPEx, on the other hand, is unique–it is a bona fide exchange–not a broker or a bulletin board, that empowers the parties to identify target assets, negotiate key, terms and execute a contract.
In addition, all of the other websites suffer from at least one of two fatal flaws.
Second, none of the other exchanges have been designed in collaboration with a large pharmaceutical company. Unsurprisingly then, none of them are used by any large pharmaceutical companies. No matter how sophisticated a site, an exchange that was developed without input from its potentially most active users will not be sustainable in the long term. “Build it and they will come” in this context has been a recipe for failure.